6
Alcon marks 20 Years in Singapore with grand opening of expanded Tuas manufacturing facility

Alcon marks 20 Years in Singapore with grand opening of expanded Tuas manufacturing facility


Alcon Marks 20 Years with Tuas Site Expansion

Photo credit: Alcon

This press release was issued by Alcon.
 

 

  • With over USD $600 million invested to date, the completed state-of-the-art manufacturing facility strengthens Alcon’s leadership in precision eye care manufacturing
  • Expansion expected to create new high-value jobs in manufacturing, quality control, and distribution management
  • Tuas facility reinforces Singapore’s position as a strategic hub for Alcon’s manufacturing, technology, and innovation efforts in the Asian region

Alcon, the global leader in eye care dedicated to helping people see brilliantly, today announced the official opening of its expanded state-of-the-art manufacturing and logistics facility in Tuas Biomedical Park, Singapore. The event was held in conjunction with the 20th anniversary of Alcon’s operations in Singapore, a meaningful milestone that highlights two decades of innovation, high-precision manufacturing, and a commitment to improving lives through better vision.

Alcon marked the occasion with a ceremony attended by Ms. Low Yen Ling, Senior Minister of State for the Ministry of Trade and Industry.

The completed Tuas facility, one of Alcon’s largest high-tech manufacturing facilities, is equipped with advanced automation, smart manufacturing systems, and industry 4.0 capabilities to meet the growing global demand for Alcon’s innovative contact lenses portfolio. It will support the global production of Alcon’s flagship PRECISION1® contact lenses, which feature proprietary SMARTSURFACE® Technology, setting new standards in comfort and clarity for millions of lens wearers worldwide.

“We are honored to celebrate this significant milestone in Singapore as part of our long-standing commitment to delivering life-changing eye care products and technologies around the world. The expanded Tuas facility will not only enhance our ability to serve patients’ ocular health needs globally, but also advance our mission to help people see brilliantly through bold innovation, our investments in training and education, and our promise of unwavering quality for customers and patients.”

Patrick Collier

Senior Vice President, Global Manufacturing and Technical Operations

Alcon

Alcon’s Bold Innovation Made in Singapore

Since establishing its first manufacturing site in Singapore in 2005, Alcon has consistently invested in the country’s talent, technology, and infrastructure, committing more than USD $600 million in investment to date. The latest completed expansion is expected to create new high-value job opportunities, including specialized roles in production operations, quality control, and distribution management.

The facility expansion reinforces Singapore's role as a key hub for Alcon's manufacturing operations in Asia. The newly completed site features dedicated production lines optimizing efficiency through processes that ensure consistent lens quality and wearer comfort.

“Alcon’s latest expansion marks an important milestone in the company’s 20-year journey in Singapore. Through close collaborations with Singapore suppliers and technology partners, Alcon has been able to enhance advanced manufacturing capabilities and drive sustainable practices here to serve global markets. We look forward to deepening our collaboration with Alcon to drive growth, innovation, and talent in Singapore’s Medtech sector.”

Goh Wan Yee

Senior Vice President, Healthcare

EDB

Driving Excellence in Sustainable Manufacturing

The new Tuas facility is designed with both operational and environmental performance in mind. Featuring high levels of automation, integrated digital systems, and sustainability-focused design, it delivers energy and water savings, waste reduction, and improved throughput. Alcon’s Tuas facility achieved zero waste to landfill, and offers scalable production capabilities to meet evolving global needs.

Investing in Talent and the Future of Eye Care

The expansion supports Alcon's vision for a world where all people have access to quality eye care. In 2024, Alcon invested USD $876 million in research and development globally, secured 37 new product approvals in major markets, initiated 57 clinical trials, and had over 70 pipeline products under development.

The Tuas facility will support Singapore’s ambition to grow its MedTech workforce, which comprises over 400 companies and employs more than 16,000 people as of 2024. Through partnerships with local educational institutions and workforce development programs such as the Talent Advancement Program and the Alcon Education Assistance Program, Alcon aims to continue nurturing capabilities in precision engineering, biomedical sciences, and AI-driven automation, contributing to the expansion and advancement of the country’s MedTech sector.

Contact Us Icon
Reach out to us for information on how we can facilitate your investment journey
Subscribe Icon
The latest business insights and news delivered to your inbox
Subscribe now